Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
Globe Newswire•01/10/2026•11:30 ET
0
Key Highlights
- ➤Trevogrumab 75 mg preserved 42.5% of lean mass loss at 52 weeks with semaglutide (REGN)
- ➤Lower-dose trevogrumab preserved almost 70% of thigh muscle otherwise lost with semaglutide alone (REGN)
- ➤Regeneron (REGN) plans a Phase 2 trial in older adults with obesity and decreased muscle mass or strength
- ➤Lower-dose trevogrumab adverse events occurred in 77% of participants versus 82% with placebo (REGN)
Expert Statements
Julio Rosenstock, Lead Principal Investigator of the COURAGE trial and Clinical Professor of Medicine, University of Texas Southwestern Medical Center, Dallas
“COURAGE demonstrated that trevogrumab, which blocks myostatin, can preserve lean mass and muscle during semaglutide-induced weight loss. These results, sustained through a full year of treatment, were further validated by MRI measurements of muscle volume supporting continued clinical development of trevogrumab and future research into muscle preservation as part of obesity care.”
Boaz Hirshberg, Senior Vice President, Clinical Development, Internal Medicine, Regeneron
“As GLP-1 receptor agonist-based medicines become foundational to obesity care, it is becoming increasingly recognized that the associated muscle loss is an increasing concern – particularly for people with sarcopenia, older adults and others where frailty is a real concern. Our COURAGE trial not only confirms this concern about muscle loss but also shows that trevogrumab can be part of the solution, addressing not the quantity, but rather the quality, of weight loss. It’s an approach we’re building across our growing pipeline.”
In a predefined MRI substudy, trevogrumab prevented 70% of muscle loss associated with semaglutide treatment
A pre-specified subgroup analysis found that patients meeting the low lean mass definition for sarcopenia had greater loss of lean mass with semaglutide, and more preservation with trevogrumab
Get started
Create a free account to read the full story.